GLP-1 Companion Foods Market (2026-2036)

The growth of this market is mainly driven by the rapid growth in the number of people using GLP-1 medications, clinical guidance emphasizing nutrition during GLP-1 therapy, and the repositioning of food portfolios by major manufacturers toward GLP-1 users. However, lower overall food consumption among GLP-1 users, regulatory limits on nutrition and health claims, high treatment discontinuation rates, and price sensitivity among consumers already paying for medication restrain the growth of this market.

Furthermore, nutrition for muscle preservation during weight loss, bundling with telehealth and pharmacy channels, and international expansion as GLP-1 access widens are expected to offer growth opportunities for the stakeholders in this market. However, limited clinical evidence for products specific to GLP-1 users, formulating for gastrointestinal tolerability and changing taste preferences, the absence of standard criteria for GLP-1 positioning, and a changing treatment landscape remain major challenges impacting the growth of this market. Additionally, explicit GLP-1 labeling and dedicated product lines, reformulation around protein and fiber, the move to smaller and more nutrient-dense portions, and the integration of nutrition into obesity care pathways are prominent trends in this market.

The GLP-1 Companion Foods Market comprises foods, beverages, and nutritional supplements formulated or positioned to meet the nutritional needs of people using GLP-1 receptor agonist medications and related incretin therapies for obesity or type 2 diabetes. Because these medications reduce appetite and food intake, users need smaller portions that deliver adequate protein, fiber, vitamins, minerals, and hydration, while minimizing gastrointestinal discomfort and preserving lean muscle mass. The market covers protein beverages and shakes, frozen and prepared meals, snacks and bars, dairy and cultured products, fiber and gut health products, dietary supplements such as multivitamins, electrolytes, and protein powders, and meal kits and delivered meals, sold through supermarkets, pharmacies, online and direct-to-consumer channels, specialty nutrition retailers, clinics, and foodservice. Products explicitly labeled for GLP-1 users are included, together with the attributable share of high-protein, high-fiber, and portion-controlled products purchased by GLP-1 users. The ecosystem spans packaged food and beverage companies, specialized nutrition and supplement brands, meal delivery services, retailers, telehealth and weight management providers, and clinicians and dietitians.

GLP-1 adoption is changing consumer food demand. Research by Cornell University, published in the Journal of Marketing Research in December 2025, estimated that GLP-1 adoption rose from 5.5% of the U.S. population in October 2023 to 8.3% in July 2024, and that about 16% of U.S. households included at least one user. Households with a GLP-1 user reduced grocery spending by 5.5% within six months of adoption, with higher-income households reducing spending by 8.6%, driven by large declines in calorie-dense, processed items, including an 11% fall in savory snacks, and cut spending at fast-food chains, coffee shops, and limited-service restaurants by 8.6%. Spending on nutrient-dense foods such as yogurt and fresh produce showed directionally positive changes.

Food companies have responded with dedicated products. Nestlé launched Vital Pursuit, a U.S. line of meals it describes as high in protein, a good source of fiber, containing essential nutrients, and portion-aligned to a weight loss medication user's appetite, together with a pre-meal drink under its Boost brand aimed at GLP-1 users. Conagra Brands began placing an On Track badge on 26 Healthy Choice products in January 2025, identifying them as high in protein, low in calories, and a good source of fiber, and describing them as GLP-1 friendly, the first major food brand to do so on-pack. Danone's Oikos brand launched a cultured dairy drink with a patented nutrient blend designed to help build and retain muscle mass during weight loss.

Clinical guidance has strengthened the case for tailored nutrition. On 30 May 2025, four professional organizations, the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, published a joint advisory, Nutritional Priorities to Support GLP-1 Therapy for Obesity, in four peer-reviewed journals. The advisory noted that GLP-1 therapies produce average placebo-adjusted weight reductions of 5% to 18% in clinical trials, but that patients face challenges including muscle and bone loss, nutrient deficiencies, and poor adherence, and it set out eight nutritional and lifestyle priorities, including adequate protein intake and resistance training to preserve lean mass.